Furthermore, the treatment with single agent targeting the cKIT, EGFR Fibroblast Growth Factor Receptor (FGFR), and Protein Kinase B (AKT) pathways did not significantly improve clinical outcome of patients with R/M ACC [56]. This evidence concerns the gene AKT1 and adrenal cortex carcinoma.